Michael Ellison, MD
Pulmonary Disease · Santa Cruz, CANPI 1861465932
Payments from drug & device makers
Across 56 payments — averaging $26.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Boehringer Ingelheim$154
- AstraZeneca$136
- Myriad Genetic Laboratories, Inc.$51
- Pulmonx Corporation$38
- Insmed, Inc.$34
- plus $46 from 2 others
What the payments were for
- Food & beverage$1,40595%
- Education$805%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 46 | $1,027 |
| Boehringer Ingelheim | 3 | $154 |
| AstraZeneca | 1 | $136 |
| Myriad Genetic Laboratories, Inc. | 1 | $51 |
| Pulmonx Corporation | 1 | $38 |
| Insmed, Inc. | 2 | $34 |
| CSL Behring | 1 | $24 |
| United Therapeutics Corporation | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,485 in reported general payments places this provider in the 50th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 23 | $315,068 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 14 | $304,505 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 307 | $236,789 |
| Breo ElliptaFluticasone/Vilanterol | 245 | $125,470 |
| NucalaMepolizumab | 12 | $43,039 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 59 | $40,006 |
| Incruse ElliptaUmeclidinium Bromide | 92 | $36,275 |
| EliquisApixaban | 39 | $32,968 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 44 | $32,686 |
| Atrovent HfaIpratropium Bromide | 31 | $22,026 |
| Spiriva RespimatTiotropium Bromide | 22 | $18,649 |
| Arnuity ElliptaFluticasone Furoate | 61 | $18,297 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 285 | $12,259 |
| Fluticasone Propionate HfaFluticasone Propionate | 25 | $11,521 |
| Wixela InhubFluticasone Propion/Salmeterol | 97 | $10,796 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $1,027 | $499,876776 claims |
| Boehringer IngelheimOfev, Combivent Respimat, Spiriva Respimat, Stiolto Respimat | $154 | $372,504102 claims |
| AstraZenecaSymbicort | $136 | $5,05518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Santa Cruz
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Sanjay VadgamaSherman Oaks$3.3M
- Rajan SaggarLos Angeles$3.3M
- Samuel LouieSacramento$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.